Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor–Positive Non‐Small Cell Lung Cancer
Cancer Reports · 2024
DOI: 10.1002/cnr2.70004 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Reports, 2024. Verfasst von Meiko Morita und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Recurrence, Local, ErbB Receptors. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Mutations in the epidermal growth factor receptor ( EGFR ) gene are the most common targetable gene alterations in non‐small cell lung cancer (NSCLC). In Japan, approximately 40% of patients who undergo surgical resection for non‐squamous NSCLC have EGFR mutations. However, no long‐term studies have been conducted including a large number of EGFR ‐positive NSCLC patients with postoperative recurrence (PR).
Methods
We conducted a retrospective observational study of the data of EGFR ‐positive NSCLC patients with PR who had undergone surgery at the Shizuoka Cancer Center between October 2002 and November 2017. We evaluated post‐recurrence overall survival (PRS) and postoperative overall survival (POS) using the Kaplan–Meier method and identify any associations between the clinical variables at recurrence and PRS using univariate and multivariate analysis.
Results
We enrolled 162 patients. The median observation time for PRS was 4.95 years (range, 0.82–13.25) and POS was 5.81 years (range, 2.84–16.71). The median PRS was 5.17 years (95% confidence interval [CI], 3.90–5.61) and POS was 7.07 years (95% CI, 5.88–8.01). Univariate analysis identified male sex (median PRS: 3.32 vs. 5.39 years; p < 0.05), bone metastasis (median PRS: 2.43 vs. 5.33 years; p < 0.05), and central nervous system (CNS) metastasis (median PRS: 3.05 vs. 5.39 years; p < 0.05) and multivariate analysis identified bone metastasis (hazard ratio [HR], 2.01; 95% CI, 1.23–3.28; p < 0.05) and CNS metastasis (HR, 1.84; 95% CI, 1.14–2.98; p < 0.05) as poor prognostic factors. The pattern of recurrence (oligo vs. non‐oligo recurrence) was not a prognostic factor. Logistic regression analysis revealed the association between sex and the presence bone/CNS metastasis at recurrence.
Conclusion
Our data may help visualize future prospects and determine the timing of osimertinib initiation. New treatment strategies need to be developed for patients with bone/CNS metastasis at the first recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
- Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
ORCID-Profile: Meiko Morita
Zitieren
APA
Morita, M., Ono, A., Sekikawa, M., Doshita, K., Miura, K., Kodama, H., Yabe, M., Morikawa, N., Iida, Y., Mamesaya, N., Kobayashi, H., Ko, R., Wakuda, K., Kenmotsu, H., Naito, T., Murakami, H., Isaka, M., Ohde, Y., & Takahashi, T. (2024). Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor–Positive Non‐Small Cell Lung Cancer. Cancer Reports. https://doi.org/10.1002/cnr2.70004
Vancouver
Morita M, Ono A, Sekikawa M, Doshita K, Miura K, Kodama H, et al. Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor–Positive Non‐Small Cell Lung Cancer. Cancer Reports. 2024. doi:10.1002/cnr2.70004
BibTeX
@article{Morita2024,
author = {Morita, Meiko and Ono, Akira and Sekikawa, Motoki and Doshita, Kosei and Miura, Keita and Kodama, Hiroaki and Yabe, Michitoshi and Morikawa, Noboru and Iida, Yuko and Mamesaya, Nobuaki and Kobayashi, Haruki and Ko, Ryo and Wakuda, Kazushige and Kenmotsu, Hirotsugu and Naito, Tateaki and Murakami, Haruyasu and Isaka, Mitsuhiro and Ohde, Yasuhisa and Takahashi, Toshiaki},
title = {Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor–Positive Non‐Small Cell Lung Cancer},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.70004}
}
EUVIMED